In this short review of the characteristics of heterogeneous nuclear RNA of normal small lymphocytes and of leukemic blast cells the author points out that the average life time of the molecules of this RNA class in both types of cell is much longer than that so far reported for rapidly proliferating cells. In both types of cell the newly synthesized RNA includes rapidly hybridizing sequences. There is evidence, although circumstantial, that in leukemic cells these sequences are markedly different from that of normal lymphocytes. In both normal lymphocytes and leukemic blast cells the rapidly hybridizing RNA sequences are in part involved in secondary structure. In fact, a significant fraction of the hnRNA appears in RNase-resistant form with double-stranded properties. About one fifth of the hnRNA molecules of normal lymphocytes carries poly(A) segments, whereas this proportion is markedly higher in leukemic cells.

Keywords:
Lymphocytes, Leukemic cell, Heterogeneous nuclear RNA, Repetitive sequences, Poly(A) sequences, Double-stranded sequences
This content is only available via PDF.
© 1975 S. Karger AG, Basel
1975
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.